PBI shared the recent significant progress in company products
PapiVax Biotech Inc. (PBI) held a product briefing on April 1, 2024, to share recent significant developments in product development with its shareholders. The event aimed to ensure that shareholders who have been quietly supporting PBI could fully understand the important achievements made last year at the National Biotechnology Research Park, including the acquisition of TriGrid electroporation assets, the establishment of a subsidiary in the United States, breakthroughs in clinical trials, and innovative patents. PBI organized this briefing within the park to provide shareholders with the opportunity to express their opinions and engage in discussions.
At the start of the meeting, Chairwoman & General Manager Lily Wu expressed heartfelt thanks to the shareholders for their active participation and conveyed gratitude for their trust and support over the past decade. She further expressed the anticipation of PBI’s limitless potential for development in the future, hoping that shareholders could witness Jiayang’s growth together.
Next, Dr. TC Wu, the Scientific Founder of PBI, commenced the meeting by sharing updates on product progress. Through a lively and engaging speech, he comprehensively introduced the urgent medical need for cervical cancer treatment, astonishing clinical data results, PBI’s competitive advantages in the market, and the outstanding features of the TriGrid instrument. He also shared PBI’s future IPO layout and prospects, providing attendees with a clearer understanding of PBI’s outlook. Throughout the sharing process, shareholders actively raised questions and provided valuable suggestions, creating a warm atmosphere that lasted until the lunch break.
Finally, Chairwoman Lily Wu sincerely thanked the shareholders for their enthusiastic participation and valuable input. She stated that PBI would continue its unremitting efforts to promote product authorization to the market and invited shareholders to join for lunch and further discussion. The PBI product development progress briefing concluded successfully.